BrainCheck Lauds Leqembi FDA Approval, Will Attend Global Alzheimer’s Association Conference

July 17, 2023 / Nueterra Capital Marketing

BrainCheck | A Nueterra Capital Portfolio Company

BrainCheck, a Nueterra Capital portfolio company that provides a comprehensive cognitive assessment and care platform for patients and practitioners, is marking the announcement of FDA approval for the drug Leqembi® as a “major milestone in the fight against Alzheimer’s disease.” The company issued a statement of their support for the drug in a press release. Kim Rodriguez, BrainCheck’s newly appointed CEO, said the platform’s early detection capabilities can help patients reap the benefits of Leqembi. “With the approval specifically focused on the treatment of patients with early forms of disease, such as mild cognitive impairment or mild dementia, early detection has never been more important.”

BrainCheck also announced that Rodriguez and Chief Revenue Officer Matt Cerullo are currently attending the Alzheimer’s Association International Conference (AAIC) in Amsterdam to “share BrainCheck’s technology with the global dementia research community.”